Related Experiment Video
Updated: Jul 14, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab
Jacqueline K Suen1, Linda Bressler, Stacy S Shord
1Department of Medicine, Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Anti-Cancer Drugs
|June 22, 2007
Summary
Cetuximab shows repeated effectiveness in a patient with advanced squamous cell skin cancer. This monoclonal antibody targets human epidermal growth factor receptor, offering a palliative option for EGFR-expressing tumors.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Nonmelanoma skin cancer is common, with squamous cell carcinoma (SCC) representing a significant portion.
- While most SCCs are curable, metastatic or recurrent cases have a poor prognosis.
Observation:
- A case report details a patient with nonresectable SCC and high human epidermal growth factor receptor (EGFR) expression.
- The patient experienced repeated positive responses to cetuximab treatment.
Findings:
- Cetuximab, a monoclonal antibody, targets the EGFR pathway.
- The study highlights repeated efficacy of cetuximab in a challenging SCC case.
Implications:
- Cetuximab is a potential palliative treatment for EGFR-expressing metastatic or recurrent SCC.
- This case supports considering cetuximab for advanced squamous cell skin cancer with strong EGFR expression.
Related Concept Videos
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...